Revolution Medicines to Host Investor Engagements
Revolution Medicines, Inc. (Nasdaq: RVMD), an innovative clinical-stage oncology company, has recently announced exciting opportunities for investor engagement. The company is at the forefront of developing targeted therapies aimed at RAS-addicted cancers. Mark A. Goldsmith, M.D., Ph.D., the Chief Executive Officer and Chairman, will represent the company as a key speaker at two upcoming prestigious healthcare conferences.
Details of the Conferences
Revolution Medicines will participate in significant events that gather key stakeholders in the healthcare sector. Below are the details of the conferences where attendees can learn more about the company's innovative approaches:
Guggenheim's Inaugural Healthcare Innovation Conference
This event will take place from November 11-13. Mark A. Goldsmith is scheduled for a fireside chat on Tuesday, November 12, at 3:00 p.m. ET. The conference is held in Boston, Massachusetts, and attendees will also have access to a webcast of the event. This is a great opportunity for investors and industry professionals to engage with thought leaders and gain insights into the future of healthcare innovations.
UBS Global Healthcare Conference
Another opportunity to hear from Revolution Medicines comes at the UBS Global Healthcare Conference, which will occur from November 11-14. Mark A. Goldsmith will also lead a session on Wednesday, November 13, at 5:00 p.m. ET. This event, set in Rancho Palos Verdes, California, promises to deliver critical discussions around advancements in healthcare and biotechnology. Webcast availability ensures that the insights shared can reach a broader audience.
Access to Webcasts
For those who cannot attend in person, the live webcasts of both events will be accessible through the "Events & Presentations" section of the Revolution Medicines website. Following the events, a replay of the sessions will be available for viewing for at least 14 days. This provides an additional avenue for stakeholders and interested parties to engage with the content discussed during the conferences.
About Revolution Medicines
Revolution Medicines has carved a niche in the oncology field by developing unique targeted therapies tailored towards RAS-addicted cancers. Their research and development pipeline features cutting-edge RAS(ON) inhibitors, including RMC-6236, RMC-6291, and RMC-9805, which are all advancing through clinical trials. The company is also exploring further therapeutic avenues through RAS(ON) mutant-selective inhibitors like RMC-5127, RMC-0708, and RMC-8839. Revolution Medicines continues to innovate with companion inhibitors such as RMC-4630 and RMC-5552, showcasing its commitment to fighting cancer at a molecular level.
Frequently Asked Questions
What is Revolution Medicines focused on?
Revolution Medicines is dedicated to developing targeted therapies for RAS-addicted cancers, focusing on innovative RAS(ON) inhibitors.
Who will speak at the upcoming conferences?
Mark A. Goldsmith, M.D., Ph.D., the CEO and Chairman, will be the featured speaker.
When are the conferences scheduled?
The Guggenheim conference is from November 11-13, and the UBS conference will occur from November 11-14.
How can I access the conference webcasts?
Live webcasts will be available on the Revolution Medicines website's "Events & Presentations" page.
What are the key products in Revolution Medicines' pipeline?
The company is developing multiple RAS(ON) inhibitors, including RMC-6236, RMC-6291, and RMC-9805, among others.